Navigation Links
EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022
Date:10/21/2013

NEW YORK, Oct. 21, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022

http://www.reportlinker.com/p01816890/EpiCast-Report-Gram-Negative-Bacterial-Pneumonia---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022

Summary Pneumonia is one of the most common infectious diseases and is caused by infectious agents such as bacteria, viruses, and fungi. Pneumonia is an acute respiratory infection that inflames the alveoli (air sacs) in the lungs through fluid or pus. The inflamed alveoli causes limited oxygen intake in the lungs and breathing difficulties for individuals, manifesting in symptoms of coughing, chest pain, and fever. Pneumonia is a major public health concern in both developed and developing countries.

Chronic diseases such as asthma, chronic obstructive pulmonary disease, and heart disease increase the risk of developing pneumonia. Elderly patients (65 years and older) have twice the incidence of hospital-acquired pneumonia compared with the adult population. Additionally, tobacco smoking has been identified as a cause of pneumonia.

In 2012, the 6MM (US, France, Germany, Italy, Spain, UK) had 4,184,449 incident cases of CAP, with 82% of that occurring in the US. By 2022, GlobalData epidemiologists forecast there will be 4,670,664 incident cases of CAP in the 6MM. In Japan, there were 40,043 cases of CAP and HAP with an annual growth rate (AGR) of 3.78%.

These 7MM are important markets for CAP and HAP during the next 10 years because these countries have a growing older population. Pneumonia incidence differs between countries, possibly due to socioeconomic factors, differences in infectious disease reporting, and heterogeneity of diagnostics. From a public health perspective, effective prevention and treatment measures should be in place to avoid disease transmission and reduce the incidence of pneumonia.

Scope

- The Gram-Negative Bacterial Pneumonia EpiCast Report provides an overview of the risk factors and epidemiological trends for pneumonia, with a focus on gram-negative bacteria, in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of incident cases of community-acquired pneumonia (CAP) segmented by sex and age (in five-year increments beginning at 0 years and ending at =85 years), incident cases of hospital-acquired pneumonia (HAP), and incident cases of ventilator-associated pneumonia (VAP). Incident HAP cases are further segmented by causative pathogens (Acinetobacter, Escherichia coli, Klebsiella, and Pseudomonas) and antibiotic resistance in these markets.- The gram-negative bacterial pneumonia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global pneumonia market. - Quantify patient populations in the global pneumonia market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for pneumonia therapeutics in each of the markets covered.1 Table of Contents1 Table of Contents 41.1 List of Tables 51.2 List of Figures 62 Introduction 72.1 Catalyst 72.2 Related Reports 72.3 Upcoming Reports 73 Epidemiology 83.1 Disease Background 83.2 Risk Factors and Comorbidities 93.2.1 Chronic Diseases Increase the Risk of Developing Pneumonia 93.2.2 Immunosuppressive Diseases Increase Risk of Pneumonia and Heightens Mortality 103.2.3 Adults are Less at Risk for HAP Compared with Elderly Patients and Children 113.2.4 Current Smokers Have 1.88 Greater Odds of Developing CAP 113.3 Forecast Methodology 123.3.1 Sources Used 133.3.2 Sources Not Used 203.3.3 Forecast Assumptions and Methods 203.4 Epidemiological Forecast of Pneumonia (2012-2022) 263.4.1 US 263.4.2 5EU 303.4.3 Japan 393.5 Discussion 433.5.1 Epidemiological Forecast Insight 433.5.2 Limitations of the Analysis 433.5.3 Strengths of the Analysis 444 Appendix 454.1 Bibliography 454.2 About the Authors 494.2.1 Epidemiologists 494.2.2 Reviewers 494.2.3 Global Director of Epidemiology and Health Policy 514.2.4 Global Head of Healthcare 524.3 About GlobalData 534.4 About EpiCast 534.5 Disclaimer 53

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Pneumonia 9

Table 2: Sources of CAP Incidence Data Used in the Epidemiology Forecast 12

Table 3: US, Incident Cases of Pneumonia by Site of Acquisition, All Ages, Both Sexes, N, 2012-2022 26

Table 4: US, Incident Cases of CAP, N, by Age, Sex, N (Row %), 2012 27

Table 5: US, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Site of Acquisition, All Ages, Both Sexes, N (Pathogen-Specific %), 2012 28

Table 6: US, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Multidrug and Carbapenem Resistance, N (Antibiotic-Resistant Pathogen-Specific %), 2012 29

Table 7: 5EU, Incident Cases of CAP, All Ages, Both Sexes, N, Select Years, 2012-2022 30

Table 8: 5EU, Incident Cases of CAP, Both Sexes, by Age, N (Row %), 2012 31

Table 9: 5EU, Incident Cases of CAP, All Ages, by Sex, N (Row %), 2012 33

Table 10: 5EU, Incident Cases of HAP, All Ages, Both Sexes, N, Select Years, 2012-2022 34

Table 11: 5EU, Incident Cases of VAP, All Ages, Both Sexes, N, Select Years, 2012-2022 35

Table 12: 5EU, Incident Cases of Gram-Negative Bacterial CAP, by Pathogen, N (Pathogen-Specific %), 2012 36

Table 13: 5EU, Incident Cases of Gram-Negative Bacterial HAP, by Pathogen, N (Pathogen-Specific %), 2012 37

Table 14: 5EU, Incident Cases of Gram-Negative Bacterial HAP, by Pathogen and Multidrug/Carbapenem Resistance, N (Antibiotic-Resistant Pathogen-Specific %), 2012 38

Table 15: Japan, Incident Cases of CAP and HAP, N, Select Years, 2012-2022 39

Table 16: Japan, Incident Cases of CAP and HAP, by Age, Sex, N (Row %), 2012 40

Table 17: Japan, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen, N (Pathogen-Specific %), 2012 41

Table 18: Japan, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Antibiotic Resistance, N and Percentage of Pathogen-Specific Cases, 2012 42

1.2 List of FiguresFigure 1: US, Incident Cases of Pneumonia by Site of Acquisition, All Ages, Both Sexes, N, 2012-2022 27Figure 2: US, Incident Cases of CAP, N, by Age, Sex, N, 2012 28Figure 3: US, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Site of Acquisition, All Ages, Both Sexes, N, 2012 29Figure 4: 5EU, Incident Cases of CAP, All Ages, Both Sexes, N, Select Years, 2012-2022 31Figure 5: 5EU, Incident Cases of CAP, Both Sexes, by Age, N (Row %), 2012 32Figure 6: 5EU, Incident Cases of CAP, All Ages, by Sex, N, 2012 33Figure 7: 5EU, Incident Cases of HAP, All Ages, Both Sexes, N, Select Years, 2012-2022 34Figure 8: 5EU, Incident Cases of VAP, All Ages, Both Sexes, N, Select Years, 2012-2022 35Figure 9: 5EU, Incident Cases of Gram-Negative Bacterial CAP, by Pathogen, N, 2012 36Figure 10: 5EU, Incident Cases of Gram-Negative Bacterial HAP, by Pathogen, N, 2012 37Figure 11: Japan, Incident Cases of CAP and HAP, N, Select Years, 2012-2022 39Figure 12: Japan, Incident Cases of CAP and HAP, by Age, Sex, N, 2012 40Figure 13: Japan, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen, N, 2012 41

To order this report: EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022 http://www.reportlinker.com/p01816890/EpiCast-Report-Gram-Negative-Bacterial-Pneumonia---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

 Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022
2. Pharma IQs Laboratory Informatics Report: Current Trends & Predictions for 2015
3. Report: Independent Drugstores, Policymakers Face New Challenges
4. Home Affairs Committees Drugs Report: Angelus Foundation Says the Prime Minister Should Not Have Rejected a Royal Commission
5. New Report: Drugstore Networks Could Save Employers, Medicare, and Medicaid $115 Billion
6. Report: Community Drugstores Tied to Medication Waste
7. Report: Upgrading Medicaid Drug Benefits Could Save Pennsylvania $896 Million
8. BioMEMS 2013 Report: Microsystem Device Market for Healthcare Applications
9. New Oral Anticoagulants Markets Research Report: New Anticoagulants and their Manufacturers Covered
10. DNA Sequencing 2013 Research Report: Market Developments, Growth Areas and Opportunities
11. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Little Rock, AR (PRWEB) , ... October 13, ... ... owned firm with locations throughout Arkansas that offers insurance and financial preparation services, ... to benefit the Rock City Rescue organization. , Rock City Rescue is a ...
(Date:10/13/2017)... ... 2017 , ... PurhealthRX , a leading Health and Nutrition Company, is ... to full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing ... easily incorporated into liquid products, while reducing costs to end users. , The team ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
Breaking Medicine News(10 mins):